Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
phase 3
Biotech
Boehringer's schizophrenia drug fails trio of phase 3 trials
Boehringer’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials.
Gabrielle Masson
Jan 16, 2025 11:58am
Galectin's stock halves after phase 3 MASH trial misses goal
Dec 20, 2024 2:40pm
Merck's HIV combo treatment meets efficacy bar in phase 3 trials
Dec 19, 2024 11:54am
J&J, Protagonist's oral psoriasis prospect scores in phase 3s
Nov 19, 2024 11:44am
Otsuka's kidney disease drug improves UPCR levels in ph. 3 trial
Oct 22, 2024 10:38am
Despite ph. 3 miss, Alkeus sees path forward for eye disease med
Sep 17, 2024 10:58am
